發(fā)布時間：2018-11-19 08:07

【摘要】：目的：通過與胰島素比較，分析二甲雙胍和格列苯脲在妊娠期糖尿�。℅estational Diabetes Mellitus, GDM）中的安全性和有效性；方法：系統(tǒng)性檢索PubMed, EMBASE, the Cochrane Central Register ofControlled Trials (CENTRAL)，和中國生物醫(yī)學生物文獻數據庫，截至2013年12月有16篇隨機對照試驗包含二甲雙胍及格列苯脲與胰島素的比較。主要結果：本研究有2665例病例納入。在巨大兒方面，格列苯脲組多于胰島素組(OR=3.299,95%CI=1.649to6.600, P=0.001），而二甲雙胍組低于格列苯脲組(OR=0.234，95%CI=0.061to0.893，P=0.033)，二甲雙胍組與胰島素組無顯著差異（P=0.198）。在孕婦體重增加方面，二甲雙胍組明顯低于胰島素組（SMD=-0.539，95%CI=-0.716to-0.362，P=0.000）。妊娠時限方面，二甲雙胍明顯短于胰島素組（SMD=-0.142，95%CI=-0.246to-0.039，P=0.007）。結論：二甲雙胍控制血糖的療效好，，母親體重增加少，有更低的糖化血紅蛋白水平，且不增加母親低血糖風險，但可能增加早產風險。格列苯脲組有更高的巨大兒發(fā)生率。
[Abstract]:Objective: to analyze the safety and efficacy of metformin and glibenclamide in gestational diabetes mellitus (Gestational Diabetes Mellitus, GDM) by comparing with insulin. Methods: PubMed, EMBASE, the Cochrane Central Register ofControlled Trials (CENTRAL), and Chinese biomedical literature database were systematically searched. As of December 2013, 16 randomized controlled trials included metformin, glibenclamide and insulin. Main results: 2665 cases were included in this study. In macrosomia, glibenclamide group was more than insulin group (OR=3.299,95%CI=1.649to6.600, P0. 001), while metformin group was lower than glibenclamide group (OR=0.234,95%CI=0.061to0.893,P=0.033). There was no significant difference between metformin group and insulin group (P = 0.198). In weight gain, metformin group was significantly lower than insulin group (SMD=-0.539,95%CI=-0.716to-0.362,P=0.000). In pregnancy duration, metformin was significantly shorter than insulin group (SMD=-0.142,95%CI=-0.246to-0.039,P=0.007). Conclusion: metformin has a good effect on blood glucose control. Mothers have less weight gain, lower glycosylated hemoglobin level and less risk of hypoglycemia, but may increase the risk of premature delivery. The glibenclamide group had a higher incidence of macrosomia.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R587.1

【參考文獻】

相關期刊論文 前3條

1 曾憲濤;曹世義;孫鳳;田國祥;;Meta分析系列之六:間接比較及網狀分析[J];中國循證心血管醫(yī)學雜志;2012年05期

2 Patricia M Kearney;Colin Baigent;Jon Godwin;Heather Halls;Jonathan R Emberson;Carlo Patrono;徐東;;選擇性環(huán)氧化酶2抑制劑和傳統(tǒng)非甾體抗炎藥增加粥樣血栓形成的風險嗎?隨機試驗的薈萃分析[J];英國醫(yī)學雜志(中文版);2006年05期

3 Gordon Guyatt;Andrew D.Oxman;Regina Kunz;James Woodcock;Jan Brozek;Mark Helfand;Pablo Alonso-Coello;Yngve Falck-Ytter;Roman Jaeschke;Gunn Vist;Elie A.Akl;Piet N Post;Susan Norris;Joerg Meerpohl;Mona Nasser;代表GRADE工作組;李幼平;楊曉妍;李鴻浩;;GRADE指南:Ⅷ.證據質量評價——間接性[J];中國循證醫(yī)學雜志;2011年12期

本文編號：2341647